Assembly Biosciences Inc (ASMB) 13F Filing Data & Analysis (Q2 2026)

ASMB ranks #4717 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ASMB is a top-conviction position for Gilead Sciences, Inc. — at 8.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Parkman Healthcare Partners LLC has added to its ASMB position for two straight quarters, increasing it by $11.3M to reach $19.8M today.

Ra Capital Management, L.p. has trimmed its ASMB position for two straight quarters, cutting it by $6.7M while still holding $28.0M.

ASMB is up 4.4% today, and institutions have been net buyers of $165.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ASMB reported a net loss of $42.0K over the trailing twelve months.

• Not yet profitable — net loss of $42.0K over the trailing twelve months
• Net income improved year over year, from -$39.0M to -$42.0K
• Operating cash flow was negative, using $41.1M in cash
• Current ratio of 5.22x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.25x equity — within a conventional range